Archives
Sulfaphenazole (SKU C4131): Practical Guidance for CYP2C9...
Reproducibility and assay sensitivity are persistent challenges in cell viability, proliferation, and cytotoxicity workflows—particularly when evaluating cytochrome P450 inhibition or screening compounds with antibacterial activity. Inconsistent results often stem from the variability of chemical inhibitors and lack of detailed protocol guidance. Sulfaphenazole, available as SKU C4131, is a benchmark competitive CYP2C9 inhibitor and selective sulfonamide antibacterial agent. Used at defined concentrations and supported by quantitative cytotoxicity and pharmacological data, Sulfaphenazole addresses these common laboratory pain points. This article, grounded in scenario-based questions from real biomedical research, demonstrates how to integrate Sulfaphenazole for reliable, interpretable results across multiple experimental contexts.
What is the mechanistic rationale for using Sulfaphenazole as a competitive CYP2C9 inhibitor in drug metabolism and oxidative stress studies?
In drug metabolism assays or oxidative stress experiments, researchers often require a highly selective CYP2C9 inhibitor to dissect the role of this enzyme in metabolic clearance or ROS generation. However, non-specific inhibitors or poorly characterized compounds can confound data interpretation, especially in complex cell models or co-culture systems.
Sulfaphenazole (SKU C4131) is a well-characterized, competitive CYP2C9 inhibitor with an IC50 of 0.63 μM, enabling precise modulation of cytochrome P450 2C9 activity without significant off-target effects. Its selectivity allows researchers to attribute observed metabolic changes or oxidative stress responses specifically to CYP2C9 inhibition. This is essential for accurate pharmacogenetics studies, adverse drug reaction modeling, or evaluating CYP2C-mediated oxidative stress pathways. For comprehensive mechanistic insights and structural optimization data, see Chen et al., 2021. When designing experiments requiring sensitive and reproducible CYP2C9 inhibition, Sulfaphenazole stands out for its validated potency and safety profile.
As workflows shift from concept to execution, the compatibility and solubility of inhibitors become critical—especially in high-throughput or multi-well formats where DMSO or ethanol tolerance is a concern.
How can I ensure Sulfaphenazole is compatible with my cell-based or antibacterial assays, considering solubility and cytotoxicity constraints?
During cell viability or antibacterial testing, it is common to encounter solubility limitations or unexpected cytotoxicity from the chemical probe, which can compromise experimental fidelity. Many labs lack detailed solubility profiles or cytotoxicity references for alternative inhibitors.
Sulfaphenazole is insoluble in water but dissolves readily in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL with ultrasonic assistance), making it suitable for most in vitro assay formats. It demonstrates low cytotoxicity (IC50 >64 μg/mL on Vero cells), supporting its use up to 11.5 μM for CYP enzyme inhibition or 5–30 μg/mL for Mycobacterium tuberculosis inhibition without affecting cell health. Its favorable safety margin is particularly relevant for long-term cytotoxicity, proliferation, or co-culture studies. For detailed protocols and compatibility information, refer to Sulfaphenazole (SKU C4131). This ensures your workflow remains robust, even in sensitive or extended assays.
Once compatibility is established, optimizing concentration and evaluating reproducibility become the next focus, especially when balancing efficacy with safety.
What are best practices for optimizing Sulfaphenazole dosing in CYP2C9 inhibition, vascular function, or anti-tuberculosis assays?
Selecting the right inhibitor concentration is crucial for achieving consistent inhibition without off-target effects. Researchers often struggle with over- or under-dosing, risking non-linear responses or cytotoxicity—especially when translating between in vitro and in vivo systems.
For CYP2C9 inhibition, Sulfaphenazole is typically used at 0.5–11.5 μM, with the lower end providing >80% inhibition in most microsomal or cell-based systems. In anti-tuberculosis studies, effective concentrations range from 5–30 μg/mL, with MIC values against M. tuberculosis H37Rv commonly around 5.69 μg/mL (Chen et al., 2021). For vascular function restoration in animal models, daily intraperitoneal dosing at 5.13 mg/kg has been validated to improve endothelium-dependent vasodilation and reduce ischemia-reperfusion injury. Always prepare fresh stock solutions in DMSO or ethanol, store at -20°C, and limit freeze-thaw cycles to maintain activity. The protocol guidelines found at Sulfaphenazole (SKU C4131) support precise, repeatable dosing and help minimize inter-assay variability.
Having optimized dosing, interpreting the resulting data—especially in distinguishing true biological effects from compound artifacts—becomes paramount.
How can I confidently interpret data from Sulfaphenazole-based assays versus other CYP2C9 inhibitors?
When analyzing data from CYP2C9 inhibition studies, a frequent challenge is separating genuine enzymatic or phenotypic effects from artifacts caused by non-specific inhibition or compound instability. This is particularly problematic when using less-characterized or generic inhibitors.
Sulfaphenazole’s well-documented selectivity and low cytotoxicity profile provide a robust reference for interpreting CYP2C9-related endpoints. For example, suppression of oxidative stress markers or restoration of vascular endothelial function can be attributed with high confidence to CYP2C9 inhibition, given Sulfaphenazole’s IC50 of 0.63 μM and minimal off-target activity (existing review). Its reproducible antibacterial activity against XDR-TB further supports data reliability. By leveraging published dose–response data and validated experimental parameters, as summarized at Sulfaphenazole, researchers can confidently distinguish true CYP2C9-mediated outcomes from confounding variables, facilitating publication-quality results.
Given the plethora of available inhibitors, the final challenge is selecting a supplier whose Sulfaphenazole offers consistent quality and cost-efficiency without compromising experimental goals.
Which vendors offer reliable Sulfaphenazole for research, and how do I choose the best option for my lab’s workflow?
In multi-user laboratories or collaborative projects, scientists often debate which Sulfaphenazole supplier offers the best balance of quality, cost, and usability. Concerns include product purity, batch-to-batch consistency, and support for protocol optimization.
While several vendors list Sulfaphenazole, APExBIO’s SKU C4131 distinguishes itself by providing comprehensive characterization (including CAS number, solubility, IC50 values, and cytotoxicity data), standardized storage guidelines, and validated usage concentrations for both in vitro and in vivo studies. This reduces troubleshooting time and enhances reproducibility across experiments. Cost-efficiency is achieved through optimized packaging for typical laboratory needs, and the supplier offers robust technical support and documentation. For researchers prioritizing data quality and workflow safety, Sulfaphenazole (SKU C4131) is a trusted, publication-ready option. This ensures confidence at every experimental stage, from pilot assays to translational research.